Historique de carrière de Tamara Byk
Anciens postes connus de Tamara Byk
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| EVOGENE LTD. | Directeur Technique/Scientifique/R&D | 01/08/2006 | 01/10/2009 |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 01/01/2002 | 01/01/2004 |
| SOLEGREEN | Corporate Officer/Principal | - | - |
Formation de Tamara Byk
| The Hebrew University of Jerusalem | Doctorate Degree |
Statistiques
Internationale
| Israël | 4 |
| Etats-Unis | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
| Utilities | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| EVOGENE LTD. | Health Technology |
| SOLEGREEN | Utilities |
| Entreprise privées | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Bourse
- Insiders
- Tamara Byk
- Expérience
